Antibiotic allergy: phenotypes, endotypes, and mechanisms
Active Cooperative Agreement Awarded Last action
- Award ID
- UG3AI190113
- Recipient
-
Mayo Clinic Jacksonville (A Nonprofit Corporation) UEI GKPBCFV1QMM3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,636,552
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 66% complete
- Place of performance
- Jacksonville, FL 32224, USA
Award details come from USAspending.gov.
Description
- Abstract
- Drug allergy is the leading cause of fatal anaphylaxis in the US, with antibiotics being the most common cause of allergic reactions. For immediate penicillin allergy, evidence supports specific antigenic determinants and an immunoglobulin (LG)e-mediated mechanism. For other antibiotics, the antigenic determinants and mechanisms are not known. For some antibiotic classes, such as cephalosporins and sulfonamides, positive skin testing with non irritant concentrations supports an LGE mechanism, but for other antibiotics, such as vancomycin and fluoroquinolones, current data suggest immediate hypersensitivity reactions occur through primarily non-lgemediated processes. Currently available tests and biomarkers for antibiotic allergy have limited utility. While fatal anaphylaxis has been associated with intravenous administration, the mechanisms supporting these observations have not yet been defined as large database studies lack accurate reaction phenotyping and structured causality assessments. Although both LGE and LGG antibodies are likely to be involved in immediate-onset allergic reactions to antibiotics, biological pathways need defining in advance of biomarker discovery given the complexity of antibiotic structures, potential epitopes, and protein and cellular interactions. In this UG3/UH3 application, we apply clinical epidemiology and translational immunology methods to enhance knowledge of immediate antibiotic allergy through extending the work of an established multi-site network of drug allergy specialists, the united states drug allergy registry (usdar) consortium. Usdar studies include a multi-site database of participants evaluated for drug allergy (n=2,432) and a biorepository from specialistconfirmed antibiotic-allergic patients (n=28). Our overall goal is to determine the phenotypes, endotypes, and mechanisms of antibiotic allergy, including investigation of mechanistic differences according to drug route through these specific aims: 1) to describe the phenotypes and endotypes of immediate-onset allergic reactions to antibiotics, and 2) to define how delivery route impacts antibiotic anaphylaxis. We will achieve these aims through leveraging usdar's existing research infrastructure and participants and leadership by two allergist/immunologist physician scientists with complementary methodologic expertise. This project aligns with NIH/niaid goals to advance drug allergy research and RFA-AL-24-002 to support research that enhances understanding of the mechanisms and management of antibiotic drug allergy.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $135,626 | |
| Amendment | $322,792 | |
| Amendment | $322,792 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $351,394 | |
| Amendment | -$351,394 | |
| Amendment | -$351,394 | |
| Amendment | $351,394 | |
| Amendment | -$351,394 | |
| Amendment | $351,394 | |
| Amendment | $351,394 | |
| Amendment | -$351,394 | |
| Amendment | $427,671 | |
| Original award | $427,671 |
Show all 16
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The General Hospital Corporation | $130,744 | |
| Vanderbilt University Medical Center | $72,058 | |
| Vanderbilt University Medical Center | $72,058 | |
| The General Hospital Corporation | $130,744 |
Quick answers
Who received award UG3AI190113?
UG3AI190113 was awarded to Mayo Clinic Jacksonville (A Nonprofit Corporation) by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 3, 2025.
How much is award UG3AI190113 worth?
$1,636,552 has been obligated on UG3AI190113.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award